We keep you up-to-date about the happenings on the field of PH and rare diseases and provide you with healthcare-related news in the European Union and beyond.
Report from IMPAHCT 2024
Approximately 150 pulmonary hypertension (PH) specialists convened in Barcelona in April 2024 for Ferrer’s 6th edition of the IMPAHCT meeting. Notably, Hall Skaara represented PHA Europe for the second time at the conference, serving as the sole patient advocate present.
Report from EPF’s AGM – Brussels 13th and 14 of April 2024
The European Patient Forum (EPF) recently convened its Annual General Meeting (AGM) in Brussels, inviting its full members to participate. The two-day event began with a focus on Artificial Intelligence (AI) on day one, followed by the official AGM proceedings on day two.
FDA recently approved Opsynvi
The FDA recently approved Opsynvi, developed by Johnson & Johnson, for treating pulmonary arterial hypertension (PAH) in adults, marking a significant advancement in PAH management.
Sotatercept approved by FDA
Merck, also known as MSD outside of the United States and Canada, has announced the FDA approval of Winrevair™ (sotatercept), a groundbreaking biologic for the treatment of adults with pulmonary arterial hypertension (PAH).
Report from SAPH2024
The Saudi Association for Pulmonary Hypertension (SAPH) hosted its 17th annual conference in Riyadh, Saudi Arabia, from February 15 to 17, 2024. The conference featured an impressive scientific program with sessions led by numerous leading PH specialists from around the world.
Report from the PVRI congress in London – 2023
The Pulmonary Vascular Research Institute (PVRI) recently concluded its annual congress in London, England. Founded in 2006 as a charitable organization, PVRI has evolved into a global network that unites leading medical professionals worldwide with a keen interest in pulmonary hypertension and pulmonary vascular disease (PVD).
15th-Year Anniversary of FCHP
The Spanish association FCHP celebrated its 15th anniversary in Madrid on December 1st. Approximately 200 guests were invited, representing a diverse group that included patients, carers, health authorities, PH researchers, PH specialists, social workers, psychologists, representatives from PHA Europe and PHA, TV celebrities, and pop musicians, to name a few.
The European Health Data Space
Pulmonary Hypertension Association Europe, as part of a large multi-stakeholder group, representing the entire spectrum of the healthcare ecosystem and consisting of 33 European patient organisations, medical associations, health research infrastructures and health industry associations, have issued a joint statement to alarm bells about the significant legislative shortcomings and uncertainties in the proposed Regulation for a European Health Data Space (EHDS).
November is Awareness Month 2023
PHA Europe is collaborating with PHA to raise awareness for Pulmonary Hypertension (PH) during the Awareness Month of November. Tailorable templates have been created for sharing on social media.